Sema4, spun out of Icahn School of Medicine, has achieved a valuation of more than $1bn following a $121m series C round.
Sema4, a US-based health information spinout from integrated health system Mount Sinai Health System, yesterday raised $121m in a series C round led by investment management company BlackRock.
Deerfield Management Company, Moore Strategic Ventures, Blackstone, Section 32, Oak HC/FT, Decheng Capital and Connecticut Innovations also took part in the round, which valued Sema4 at more than $1bn post-money.
Sema4 provides screening services to help diagnose, treat and prevent disease. The company initially focused on producing models for reproductive health but has since added precision oncology and Covid-19 to its capabilities.
Andrew Elbardissi, a partner at Deerfield, has joined Sema4’s board of directors.
The company was formed by Mount Sinai in 2017 with a “substantial investment” from the health system. Its technology was developed within Mount Sinai’s private education college, Icahn School of Medicine.
Blackstone, Section 32, Oak HC/FT, Decheng Capital and Connecticut Innovations provided $120m…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
